Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial

Urologia Internationalis
Saddam Al DemourAbdalla Awidi

Abstract

This open label, phase I clinical trial (NCT02945462) using 2 consecutive intracavernous autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) for the first time in the treatment of diabetic patients with erectile dysfunction (ED). The primary outcome is to assess the safety and tolerability of intracavernous autologous BM-MSCs, the secondary outcome is to assess efficacy of the procedure. Four diabetic patients with refractory ED were included. Two consecutive intracavernous autologous BM-MSC injections were performed. Tolerability was assessed immediately and at 24 h, safety was evaluated for 2 years. Efficacy was assessed using International Index of Erectile Function-15 (IIEF-15) and Erection Hardness Score (EHS) for 12 months. procedure was well tolerated and no patients reported significant adverse effects. There was significant improvement of IIEF-15 and EHS; IIEF-15 (p = 0.04), Erectile Function (p = 0.03), Sexual Desire (p = 0.04), Intercourse Satisfaction (p = 0.04), and Overall Satisfaction (p = 0.04). This is the first human study with proven tolerability, safety and efficacy of intracavernous autologous BM-MSC injections for treatment of diabetic patients with ED.

Citations

Oct 12, 2018·Expert Opinion on Biological Therapy·Serap GurWayne J G Hellstrom
Sep 1, 2019·Medical Sciences : Open Access Journal·Eric Chung
Jan 17, 2020·Investigative and Clinical Urology·Jong Keun KimChoung-Soo Kim
Mar 24, 2020·The World Journal of Men's Health·Soyeun KimMahadevan Raj Rajasekaran
May 1, 2020·International Journal of Impotence Research·Mingyue He, Ernst R von Schwarz
Feb 12, 2019·F1000Research·Sarah C KrzastekJason R Kovac
Jun 26, 2020·Frontiers in Cell and Developmental Biology·Xueke ZhouXin Li
Aug 9, 2020·Frontiers in Cell and Developmental Biology·Matthew H ForsbergChristian M Capitini
Jan 10, 2021·Current Urology Reports·Wade MunceyAram Loeb
Jan 17, 2021·International Journal of Impotence Research·S T HansenL Lund
Jan 10, 2021·Medicines·Vassilis ProtogerouTheodoros Troupis
Oct 24, 2019·Sexual Medicine Reviews·Soum D LokeshwarRanjith Ramasamy
Aug 23, 2020·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·W AkakpoR Yiou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.